Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Pussard, E.
Right arrow Articles by Verdier, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pussard, E.
Right arrow Articles by Verdier, F.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of Antimicrobial Chemotherapy (1994) 34, 803-808
© 1994 The British Society for Antimicrobial Chemotherapy

brief-report

Pharmacokinetics and metabolism of amopyroquin after administration of two doses of 6 mg/kg im 24 h apart to healthy volunteers

E. Pussarda, D. Chassardb, F. Claviera, Ph. Bryc and F. Verdiera

aInstitut National de la Santé et de la Recherche Médicale, Unité 13 and Institut de Médecine et d'Epidémiologie Africaines, Hôpital Claude Bernard 75944 Paris Cedex 19 bInstitut Aster 75015 Paris cParke-Davis Courbevoie, France

Received 6 January 1994; accepted 7 June 1994

Twelve healthy volunteers received two doses of amopyroquin 6 mg/kg im 24 h apart. Blood and plasma concentrations of amopyroquin and two metabolites were assayed by HPLC from 0 to 48 h. Half-life values for amopyroquin, calculated from 0 to 48 h whole-blood and plasma samples were 13.9 ± 9.1 and 18.3 ± 6.8 h respectively. Two metabolites were detected in blood and they had very low in-vitro activity against Plasmodium falciparum compared with the parent drug. Neither hypotension nor lengthening of QRS complex were observed in any volunteers and hepatic enzymes remained in the normal range despite a transitory increase. These results confirm that unchanged amopyroquin accounts for antimalarial activity in vivo and that two doses of 6 mg/kg are well tolerated.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.